Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (GB:0R1F)
LSE:0R1F
Bristol-Myers Squibb (0R1F) Share Price & Analysis
2 Followers
0R1F Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$47.04 - $67.89
Previous Close$49.24
Volume11.96K
Average Volume (3M)181.16K
Market Cap
$99.29B
Enterprise Value$126.84B
Total Cash (Recent Filing)$12.28B
Total Debt (Recent Filing)$39.77B
Price to Earnings (P/E)12.8
Beta0.45
Next Earnings
Apr 25, 2024EPS Estimate
-$4.44Next Dividend Ex-DateN/A
Dividend Yield4.71%
Share Statistics
EPS (TTM)3.86
Shares Outstanding2,022,193,411
10 Day Avg. Volume107,296
30 Day Avg. Volume181,157
Standard Deviation0.07
R-Squared0.03
Alpha0.00433
Financial Highlights & Ratios
Price to Book (P/B)-5.27
Price to Sales (P/S)2.78
Price to Cash Flow (P/CF)5.80
P/FCF Ratio5.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda7.21
Forecast
1Y Price Target
$54.08Price Target Upside10.34% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bristol-Myers Squibb News
PremiumCompany Announcements
Bristol-Myers Squibb Q1 Earnings Call Strategy Insights
Bulls Say, Bears Say
Bulls Say
Operational EfficiencyImprovements in operational expenditure efficiency may lead to higher earnings per share, reflecting the company's successful cost management strategies.
Product SalesLegacy products like Eliquis could exceed sales expectations due to enduring strength in the US market, hinting at sustained demand and revenue potential.
Valuation And Investment OpportunityWith a valuation significantly lower than typical for its industry, the stock represents a potentially attractive investment opportunity for long-term gains.
Bears Say
Financial PerformanceOpdivo could miss sales expectations due to buying patterns and weak script performance.
Market CompetitionIntensifying competition could lead to Abecma falling short of sales expectations.
Regulatory ConcernsReleased FDA briefing documents raise significant concerns about Abecma's early higher incidence of death.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.30% Insiders
24.11% Mutual Funds
23.86% Other Institutional Investors
51.73% Public Companies and
Individual Investors
0R1F FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest share price was $47.04 and its highest was $67.89 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 25, 2024 which is yesterday.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 02, 2024. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.554 by $0.146.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is -$4.44.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,026,758,700 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.7 in its last earnings report, beating expectations of $1.554. Following the earnings report the stock price went down -0.231%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$54.08 (10.34% Upside)
$54.08 (10.34% Upside)
Blogger Sentiment
Bullish
GB:0R1F Sentiment 92%
Sector Average 70%
Sector Average 70%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.75%
12-Months-Change
Fundamentals
Return on Equity
26.53%
Trailing 12-Months
Asset Growth
-1.72%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
0R1F Company Deck
---
0R1F Earnings Call
Q4 2024
0:00 / 0:00
---
0R1F Stock 12 Months Forecast
Average Price Target
$54.08
▲(10.34% Upside)
Technical Analysis
Best Analysts Covering 0R1F
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+14.39%
reiterated a sell rating 17 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +14.39% per trade.
---